Antimicrobials in patients with hematologic malignancies and recipients of hematopoietic cell transplantation and other cellular therapies
Details
Publication Year 2023-08-18,Volume 25,Issue #Suppl 1,Page e14129
Journal Title
Transplant Infectious Disease
Publication Type
Review
Abstract
BACKGROUND: Appropriate use of antimicrobials for hematologic malignancy, hematopoietic stem cell transplant recipients, and other cellular therapies is vital, with infection causing significant morbidity and mortality in this unique population of immunocompromised hosts. However, often in this population the choice and management of antimicrobial therapy is complex. When selecting an antimicrobial agent, key considerations include the need for dose adjustments due to renal or hepatic impairment, managing drug interactions, the potential for additive drug toxicity among those receiving polypharmacy and therapeutic drug monitoring. Other factors include leveraging pharmacodynamic principles to enable optimization of directed therapy against challenging pathogens, as well as judicious use of antimicrobials to limit drug resistance and adverse drug reactions. SUMMARY: This review summarizes the clinical considerations for commonly used antimicrobials in this setting, including antibacterial, antiviral, and antifungal agents.
Publisher
Wiley
Keywords
antimicrobials; chimeric antigen receptor T cell (CAR-T); hematopoietic cell transplantation (HCT)
Department(s)
Infectious Diseases
PubMed ID
37594221
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-11-14 12:42:01
Last Modified: 2024-09-05 06:55:58

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙